SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities

Molecular Cancer Therapeutics

Volumn 11, Issue 8, 2012, Pages 1637-1649

  Alam, Antoine ^a   Blanc, Isabelle ^a   Gueguen Dorbes, Geneviève ^a   Duclos, Olivier ^a   Bonnin, Jacques ^a   Barron, Pauline ^a   Laplace, Marie Claude ^a   Morin, Gaelle ^a   Gaujarengues, Florence ^a   Dol, Frédérique ^a   Hérault, Jean Pascal ^a   Schaeffer, Paul ^a   Savi, Pierre ^a   Bono, Françoise ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; SAR 131675; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; EMBRYO; HUMAN; HUMAN CELL; LYMPHANGIOGENESIS; MACROPHAGE FUNCTION; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; FEMALE; HUMANS; LYMPHANGIOGENESIS; LYMPHOCYTES; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NAPHTHYRIDINES; NEOPLASM METASTASIS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN KINASE INHIBITORS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZEBRAFISH;

EID: 84864879183     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0866-T     Document Type: Article

References (50)

1. Sleeman JP, Thiele W. Tumor metastasis and the lymphatic vasculature. Int J Cancer 2009;125:2747-56.
2. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann N Y Acad Sci 2008;1131:225-3.
3. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010;140:460-76.
4. Gombos Z, Xu X, Chu CS, Zhang PJ, Acs G. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res 2005;11:8364-71. (Pubitemid 41746949)
5. Shida A, Fujioka S, Kobayashi K, Ishibashi Y, Nimura H, Mitsumori N, et al. Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int J Clin Oncol 2006;11:38- 43.
6. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006;66:2650-7.
7. Norrmen C, Tuomas T, Petrova TV, Kari A. Biological basis of therapeutic lymphangiogenesis. Circulation 2011;123:1335-51.
8. Achen MG, Jeltsch M, Kukk E, M€akinen T, Vitali A, Wilks AF, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998;95:548-53. (Pubitemid 28083780)
9. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) andKDR(VEGFR-2) receptor tyrosine kinases.EMBOJ 1996;15:1751. (Pubitemid 26112397)
10. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998;282:946-9. (Pubitemid 28507528)
11. Covassin LD, Villefranc JA, Kacergis MC, Weinstein BM, Lawson ND. Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. Proc Natl Acad Sci U S A 2006;103:6554-9.
12. Haiko P, Makinen T, Keskitalo S, Taipale J, Karkkainen MJ, Baldwin ME, et al. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol Cell Biol 2008;15:4843-50.
13. Alam A, Herault JP, Barron P, Favier B, Fons P, Delesque-Touchard N, et al. Heterodimerization with vascular endothelial growth factor recep-tor- 2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem Biophys Res Commun 2004;324:909- 15.
14. Nilsson I, Bahram F, Li X, Gualandi L, Koch S, Jarvius M, et al. VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J 2010;29:1377-88.
15. Kubo H, Fujiwara T, Jussila L, Hashi H, Ogawa M, Shimizu K, et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 2000;96:546-53. (Pubitemid 30463374)
16. Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008;454:656-60.
17. Su JL, Chen PS, Chien MH, Chen PB, Chen YH, Lai CC. Further evidence for expression and function of the vegf-c/vegfr-3 axis in cancer cells. Cancer Cell 2008;13:557.
18. Donnem T, Al-Shibli K, Al-Saad S, Delghandi MP, Busund L-T, Bremnes RM. VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: Inverse correlation between expression in tumor and stromal cells. Lung Cancer 2009;63:277-83.
19. Garces CA, Kurenova EV, Golubovskaya VM, Cance WG. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res 2006; 66:1446-54. (Pubitemid 43259925)
20. Kurenova EV, Hunt DL, He D, Fu AD, Massoll NA, Golubovskaya C, et al. Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo . Cell Cycle 2009;8:2266-80.
21. Witte D, Thomas A, Ali N, Carlson N, Younes M. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 2002;22:1463- 6.
22. Kodama M, Kitadai Y, Tanaka M, Kuwai T, Tanaka S, Oue N, et al. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Clin Cancer Res 2008;14:7205-14.
23. Hamrah P, Chen L, Zhang Q, Dana MR. Novel expression of vascular endothelial growth factor (VEGFR-3) and VEGF-C on corneal Dendritic cells. Am J Pathol 2003;163:57-68. (Pubitemid 36759591)
24. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-50. (Pubitemid 38544126)
25. Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H. Inflammationinduced lymphangiogenesis in the cornea arises from CD11b positive macrophages. J Clin Invest 2005;115:2363-72. (Pubitemid 41266198)
26. Shin YJ, Choi JS, Choi JY, Hou Y, Cha J-H, Chun MH, et al. Induction of vascular endothelial growth factor receptor-3 mRNA in glial cells following focal cerebral ischemia in rats. J Neuroimmunol 2010;229: 81-90.
27. Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest 2005;115:247-57. (Pubitemid 40385467)
28. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002;161:947-56. (Pubitemid 34988382)
29. Yang H, Kim C, Kim MJ, Schwendener RA, Alitalo K, Heston W, et al. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer 2011;10:36.
30. Kerjaschki D. The crucial role of macrophages in lymphangiogenesis. J Clin Invest 2005;115:2316-9. (Pubitemid 41266190)
31. Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, et al. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 2006;139:839-46. (Pubitemid 43902914)
32. Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhozhij S, et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 2010;116:829-40.
33. Yan A, Avraham T, Zampell JC, Aschen SZ, Mehrara BJ. Mechanisms of lymphatic regeneration after tissue transfer. PLoS One 2011;6: e17201.
34. Attout T, Hoerauf A, Dénécé G, Debrah AY, Marfo-Debrekyei Y. Lymphatic vascularisation and involvement of Lyve-1+ macrophages in the human onchocerca nodule. PLoS One 2009;4:e8234.
35. Favier B, Alam A, Barron P, Bonnin J, Laboudie P, Fons P, et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 2006;108:1243-50. (Pubitemid 44232021)
36. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effect of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808- 12.
37. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998;58:1486-93. (Pubitemid 28193612)
38. Patyna S, Arrigoni C, Terron A, Kim TW, Heward JK, Vonderfecht SL, et al. Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors. Toxicol Pathol 2008;36: 905-16.
39. Chang L K, Garcia-Cardena G, Farnebo F, Fannon M, Chen E J, Butterfield C, et al. A dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci 2004;101:11658-63.
40. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenicmice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315:115- 22.
41. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15: 232 - 9.
42. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P. Inflam-mation- mediated promotion of invasion and metastasis. Cancer Metastasis Rev 2010 29:243-8.
43. Pytowski B, Goldman J, Persaud K, Wu Y, Witte L, Hicklin DJ, et al. Complete and specific inhibition of adult lymphatic regeneration by a novelVEGFR-3 neutralizingantibody. J NatlCancer Inst 2005;97:14-21.
44. Karpanen T, Wirzenius M, kinen TM, Veikkola T, Haisma HJ, Achen MG, et al. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Am J Pathol 2006;169:708-18. (Pubitemid 44156326)
45. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788- 95.
46. Ober X. VEGFc is required for vascular development and endoderm morphogenesis in zebrafish. EMBO Rep 2004;5:78 -84.
47. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
48. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31.
49. Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 2007;67: 593-99. (Pubitemid 46192197)
50. Nykänen AI, Sandelin H, Krebs R, Keränen MA, Tuuminen R, Kärpänen T, et al. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. Circulation 2010;121:1413-22.